Autres langues Summit Therapeutics Inc.

Actions

SMMT

US86627T1088

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 16:03:19 20/08/2026			Varia. 5j.	Varia. 1 janv.
12,51 ^USD	-4,58%		-9,79%	-27,79%

12/08	Summit Therapeutics annonce que son partenaire Akeso a obtenu l'approbation en Chine pour l'ivonescimab dans le traitement du cancer du poumon non à petites cellules épidermoïde	MT
12/08	Summit Therapeutics Inc. : Leerink Partners davantage positif, passe à neutre	ZM

Autres langues

13/08	Summit Therapeutics - Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
12/08	Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC
12/08	Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
05/08	Summit Therapeutics Expands Ivonescimab Global Development Program With Phase II/III Harmonigu1 Study In First-Line Bladder Cancer
05/08	Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
27/07	Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
23/07	Summit Therapeutics Q2 Adjusted Loss Widens
23/07	Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q2 Adjusted Loss $0.19 per Share, vs. FactSet Est of $-0.17
23/07	Summit Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
23/07	Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
22/07	Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
22/07	Summit Therapeutics Announces Updated Overall Survival Results From Global Phase III HARMONi Clinical Trial Of Ivonescimab Plus Chemotherapy
22/07	Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
16/07	Kalshi to allow bets on clinical trials, FDA decisions
16/07	Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
14/07	Summit Therapeutics Inc. Signs Agreement to Sell Ridinilazole to Biossil, Inc
14/07	Summit Therapeutics Divests Ridinilazole Asset to AI Biopharma Biossil
14/07	Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
22/06	Analyst recommendations: Accenture, Conocophillips, Diamondback Energy, Oracle, Applied Materials…
12/06	Summit Therapeutics Insider Bought Shares Worth $49,987,200, According to a Recent SEC Filing
11/06	Summit Therapeutics Withdraws Public Offering Due to Market Conditions
09/06	Summit Therapeutics Launches $500 Million Common Stock Public Offering
09/06	Summit Therapeutics Announces Proposed Public Offering of Common Stock
04/06	Summit Therapeutics Insider Bought Shares Worth $722,250, According to a Recent SEC Filing
04/06	Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference